JPI InvestFranΓ§ais
JPI AI Analyst AI assistant Β· JPI Invest
Answers based on the tool's data Β· not financial advice Β· full analysis (free)
All stocks β€Ί Health Care β€Ί SOLV

Are analysts right about Solventum (SOLV)?

Health Care Β· price $90.93 Β· median target $100 (+10%)
In short β€” Over the past 12 months, 11% of analyst price targets on Solventum turned out profitable, for an average return of -7% (across 9 timestamped calls). The current consensus is "Buy" with a median price target of $100 (+10% vs the current $90.93, from 9 analysts).

πŸ“ˆ See the interactive version (live chart) β†’

πŸ”— Related pages on Solventum β€” Financials & fundamentals  Β·  If I had invested
Current price
$90.93
Median target (12 mo)
$100 +10%
Analyst accuracy (1 yr)
11%
Avg return / call (1 yr)
-7%
πŸ’° Performance & Β« if I invested Β» πŸ“Š Interactive analysis

Historical analyst accuracy

For Solventum, we replayed every analyst price target of the past 12 months and measured the real outcome: 11% were profitable, average return -7% (9 calls). At 3 months: -1% average return (35% profitable). The higher the %, the more often analysts were right on this stock.

Most reliable analysts on this stock (past track record)

Their past track record on this stock (targets replayed against real prices) β€” not a forecast of what will happen.

Not enough scored calls for a reliable ranking.

Valuation

Is Solventum overvalued, and is it a good time to buy Solventum right now? If you're wondering, here's a recap to make up your own mind: Solventum's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.

The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β€” but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.

MetricSolventumSector median (Health Care)
P/E11.229.4
Forward P/E12.617.1
Net margin17%12%

πŸ‘‰ Solventum trades below its sector median (11.2 vs 29.4) β€” potentially undervalued, or lower expected growth.

πŸ“– P/E, PEG, margin…: see the glossary

Frequently asked questions

Is Solventum a buy right now?

The analyst consensus on Solventum (SOLV) is "Buy" (20 bullish, 1 bearish calls over 12 months). This is not advice: historically, 11% of their targets on this stock turned out profitable over 1 year.

What is Solventum's price target?

The median 12-month price target is $100 (+10% vs $90.93), ranging from $60.00 to $105 (9 analysts).

Are analysts accurate on Solventum?

Over 1 year, 11% of analyst targets on Solventum were profitable, for an average return of -7% (across 9 timestamped calls). This is JPI Invest's accuracy metric.

What is the Solventum stock forecast?

Analysts target a median of $100 within 12 months, i.e. +10% vs the current price. The most bullish targets $105, the most cautious $60.00.

What is the Solventum stock forecast for 2026 or long term (2030)?

Note: analyst targets are 12-month (median $100, +10%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (11%), and the stock's past trajectory.

Is Solventum overvalued?

Its P/E is 11.2, forward P/E 12.6. A forward P/E lower than the current P/E means earnings are expected to grow.

πŸ“Š See the full interactive analysis of Solventum β†’

What is JPI Invest?

JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β€” on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.

Explore JPI Invest for free β†’ How it works: the method β†’

⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.